

Tao Liu, Zhong-Miao Xu and  
Yong-Zhou Hu\*Zhejiang University, Department of Medicinal  
Chemistry, College of Pharmaceutical Science,  
Hangzhou 310031, Zhejiang, People's Republic  
of ChinaCorrespondence e-mail:  
huyz@zjuem.zju.edu.cn


## Key indicators

Single-crystal X-ray study  
 $T = 296\text{ K}$   
Mean  $\sigma(\text{C}-\text{C}) = 0.004\text{ \AA}$   
 $R$  factor = 0.043  
 $wR$  factor = 0.088  
Data-to-parameter ratio = 14.4For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.2'-Hydroxy-3'-(morpholin-4-yl-methyl)-  
4',6'-dimethoxy-2-chloro-chalcone

In the title compound,  $\text{C}_{22}\text{H}_{24}\text{ClNO}_5$ , the carbonyl group is in an *s-cis* configuration with respect to the olefinic double bond. In the crystal structure, there are weak  $\pi$ -stacking interactions but there are no significant intermolecular hydrogen bonds.

## Comment

Chalcones possess anti-inflammatory, antimalarial and anti-fertility activities, and are also reported as having antitumor activity (De Vincenzo *et al.*, 1995; Pettit *et al.*, 2001; Kumar *et al.*, 2003). With this in mind, a series of chalcones have been synthesized in our lab and have been evaluated for antitumor activity *in vitro* against various human tumor cell lines. Among them, the title compound has a broad antitumor spectrum and low micromolar  $\text{IC}_{50}$  ranging from 4.8 to 22.7  $\mu\text{mol l}^{-1}$  against six human tumor cell lines. In order to obtain detailed information on its molecular conformation in the solid state, an X-ray structure determination of the title compound, (I), has been carried out.



The title molecule is illustrated in Fig. 1. The configuration of the carbonyl group with respect to the olefinic double bond is *s-cis*, which is the same as in two related structures (Ravishankar *et al.*, 2003; Moorthi *et al.*, 2005). The *trans* arrangement of the H atoms in the  $-\text{CH}=\text{CH}-$  group is consistent with the solution-phase  $^1\text{H}$  NMR studies ( $J = 15.6\text{ Hz}$ ; Li & Su, 1994). The atoms in the unsaturated ketone group are essentially coplanar in accordance with the  $\pi$ -electron conjugation. The exocyclic angles around C10 deviate from the normal trigonal value of  $120^\circ$ , with a larger C11—C10—C9 angle of  $125.4(3)^\circ$  and a smaller C15—C10—C9 angle of  $118.6(3)^\circ$ . This may be the result of the intramolecular  $\text{O}-\text{H}\cdots\text{O}$  hydrogen bond (Table 1). In the crystal structure, the only significant intermolecular interactions

Received 5 September 2005  
Accepted 19 September 2005  
Online 21 September 2005

present are weak  $\pi$  stacking, where the central aromatic ring (C10–C15) and the *p*-chlorobenzene ring (C1–C6), from pairs of molecules related by centers of symmetry, are separated by a centroid–centroid distance of 3.660 (2) Å and a perpendicular distance of 3.49 Å (Fig. 2).

### Experimental

The title compound was obtained from phloroglucinol *via* the Hoesch reaction (Gulati *et al.*, 1943), etherification (Juntend & Junte, 1988), Aldol condensation (Bu *et al.*, 1997) and the Mannich reaction (Wilds *et al.*, 1963). A crystal suitable for crystallographic study was obtained by slow crystallization from acetone at room temperature.

#### Crystal data

$C_{22}H_{24}ClNO_5$	$D_x = 1.336 \text{ Mg m}^{-3}$
$M_r = 417.89$	Mo $K\alpha$ radiation
Monoclinic, $C2/c$	Cell parameters from 28 reflections
$a = 13.408 (2) \text{ \AA}$	$\theta = 2.9\text{--}14.8^\circ$
$b = 10.517 (2) \text{ \AA}$	$\mu = 0.22 \text{ mm}^{-1}$
$c = 29.505 (6) \text{ \AA}$	$T = 296 (2) \text{ K}$
$\beta = 92.90 (2)^\circ$	Plate, yellow
$V = 4154.9 (13) \text{ \AA}^3$	$0.60 \times 0.50 \times 0.12 \text{ mm}$
$Z = 8$	

#### Data collection

Siemens P4 diffractometer	$R_{\text{int}} = 0.033$
$\omega$ scans	$\theta_{\text{max}} = 25.5^\circ$
Absorption correction: $\psi$ scan (SHELXTL; Bruker, 1997)	$h = 0 \rightarrow 16$
$T_{\text{min}} = 0.874$ , $T_{\text{max}} = 0.974$	$k = 0 \rightarrow 12$
4451 measured reflections	$l = -35 \rightarrow 35$
3872 independent reflections	3 standard reflections
1515 reflections with $I > 2\sigma(I)$	every 97 reflections
	intensity decay: 3.3%

#### Refinement

Refinement on $F^2$	$w = 1/[\sigma^2(F_o^2) + (0.0262P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.043$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.088$	$(\Delta/\sigma)_{\text{max}} < 0.001$
$S = 0.81$	$\Delta\rho_{\text{max}} = 0.17 \text{ e \AA}^{-3}$
3872 reflections	$\Delta\rho_{\text{min}} = -0.17 \text{ e \AA}^{-3}$
269 parameters	Extinction correction: SHELXL97
H atoms treated by a mixture of independent and constrained refinement	Extinction coefficient: 0.00184 (12)


**Table 1**

Hydrogen-bond geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$O5-HO\cdots O2$	0.90 (3)	1.62 (3)	2.452 (3)	152 (3)


All H atoms were positioned geometrically and allowed to ride on their attached atoms, with O–H, C–H(CH), C–H(CH<sub>2</sub>) and C–H(CH<sub>3</sub>) distances of 0.90, 0.93, 0.97 and 0.96 Å, respectively. The isotropic displacement parameters of the H atoms were fixed at  $1.7U_{\text{eq}}(\text{O})$  or  $1.2U_{\text{eq}}(\text{C})$ . The small ratio of observed to unique reflections (39%) limits the reliability of the structure.

Data collection: XSCANS (Bruker, 1997); cell refinement: XSCANS; data reduction: SHELXTL (Bruker, 1997); program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: SHELXTL and PLATON (Spek, 2003); software used to prepare material for publication: SHELXTL.



**Figure 1**

View of (I), showing the atom-labeling scheme and displacement ellipsoids at the 40% probability level.



**Figure 2**

Packing diagram (PLATON; Spek, 2003) of (I), showing the weak  $\pi$ -stacking interactions in the center of the unit cell. H atoms have been omitted.

X-ray data were collected at Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences.

### References

- Bruker (1997). SHELXTL (Version 5.10) and XSCANS (Version 2.1). Bruker AXS Inc., Madison, Wisconsin, USA.
- Bu, X. Y., Zhao, L. Y. & Li, Y. L. (1997). *Synthesis*, **11**, 1246–1248.
- Pouget, C., Lauthier, F., Simon, A., Fagnere, C., Basly, J.-P., Delage, C. & Chulia, A.-J. (2001). *Bioorg. Med. Chem. Lett.* **11**, 3095–3097.
- De Vincenzo, R., Scambia, G., Benedetti, P. P., Ranelletti, F. O., Bonanno, G., Ercoli, A., Delle, M. F., Ferrari, F., Piantelli, M. & Mancuso, S. (1995). *Anticancer Drug Des.* **10**, 481–490.
- Gulati, K. C., Seth, S. R. & Venkataraman, K. (1943). *Org. Synth. Coll. Vol. II*, p. 522.
- Juntend, K. Y. T. & Junte, T. S. T. (1988). European Patent 0292576.
- Li, Z. D. & Su, G. B. (1994). *Acta Cryst.* **C50**, 126–127.
- Moorthi, S. S., Chinnakali, K., Nanjundan, S., Unnithan, C. S., Fun, H.-K. & Yu, X.-L. (2005). *Acta Cryst.* **E61**, o483–o485.
- Ravishankar, T. K., Chinnakali, S., Nanjundan, S., Radhakrishnan, A. U. & Fun, H. K. (2003). *Acta Cryst.* **E59**, o138–o140.
- Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Kumar, S. K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N. E. & Khan, S. R. (2003). *J. Med. Chem.* **46**, 2813–2815.
- Wilds, A. L., Nowak, R. M. & McCaled, K. E. (1963). *Org. Synth. Coll. Vol. IV*, p. 281.